Affordable Access

Publisher Website

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis

Authors
Journal
Pediatric Rheumatology
1546-0096
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
9
Identifiers
DOI: 10.1186/1546-0096-9-s1-p135
Keywords
  • Poster Presentation
Disciplines
  • Biology
  • Medicine

Abstract

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis POSTER PRESENTATION Open Access Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis O Nemiche1*, R Dagner1, P Quartier1, R Cimaz2, O Richer3, P Pillet3, M Hofer4 From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. 14-18 September 2011 Background The anti- IL-6 Receptor monoclonal antibody Tocilizu- mab (TCZ) has demonstrated its efficacy in Japanese children with systemic onset juvenile idiopathic arthritis (SJIA). Aim To evaluate the efficacy and safety of TCZ in European patients with active SJIA outside a clinical trial (off-label use). Patients and methods Retrospective review of the files of the patients treated by TCZ in two French, one Swiss and one Italian center. Response to treatment was defined as control of the fever and systemic features for at least 7 days, Improve- ment of the pediatric ACR score and normalization of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also considered. Results 18 patients aged 4-15 years were included. The median disease duration at treatment onset was 4.7 years (0.4- 8.8). The median dose of prednisone at TCZ onset was 0.63mg/kg/d. Four patients were also on MTX. Fourteen patients had previously failed to respond one or several biologics, including anti-TNF alpha in 10 cases, anakinra in 14 and canakinumab, in 4. All patients but 4 had active systemic and polyarticular features at TCZ onset. The doses of TCZ ranged between 6 and 12 mg/kg every other week at treatment onset. The mean follow- up on TCZ was 18.2 months (range0.5-48). 90% improvement of the pediatric ACR score was achieved by 9 patients after 3 months. The dose of steroids was tapered in most cases (11/14) within 3 months, and five patients could discontinue steroid treatment after 12 months. TCZ treatment was withdrawn in 5 children for adverse events: a

There are no comments yet on this publication. Be the first to share your thoughts.